Immune response to controlled release of immunomodulating peptides in a murine experimental autoimmune encephalomyelitis (EAE) model

Journal of Controlled Release

Volumn 141, Issue 2, 2010, Pages 145-152

  Zhao, Hong ^a   Kiptoo, Paul ^a   Williams, Todd D ^b   Siahaan, Teruna J ^a   Topp, Elizabeth M ^a  

^a UNIVERSITY OF KANSAS   (United States)

^b UNIVERSITY OF KANSAS   (United States)

Author keywords

EAE; Microparticles; PLP BPI peptides; Poly(D,L lactide)

Indexed keywords

ANTIGENIC PEPTIDES; BODY WEIGHT; CONTROLLED RELEASE; DOSING FREQUENCY; EAE; EXPERIMENTAL AUTOIMMUNE ENCEPHALOMYELITIS; IMMUNE RESPONSE; MICRO-PARTICLES; MULTIPLE SCLEROSIS; OVERALL SURVIVAL; PLGA MICROPARTICLES; POLY (D ,L-LACTIDE); POLY-LACTIDE-CO-GLYCOLIDE; T CELL ACTIVATION; TREATMENT GROUP; WATER EMULSION;

AMINES; EMULSIFICATION; FLUORINE CONTAINING POLYMERS; IMMUNOLOGY; TOXICITY;

PEPTIDES;

ACETYL PROTEOLIPID PROTEIN BIFUNCTIONAL PEPTIDE INHIBITOR; IMMUNOMODULATING AGENT; POLYGLACTIN; PROTEOLIPID PROTEIN; UNCLASSIFIED DRUG;

ALLERGIC ENCEPHALOMYELITIS; ANAPHYLAXIS; ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; BODY WEIGHT; CONTROLLED DRUG RELEASE; CONTROLLED STUDY; DRUG EFFICACY; EVAPORATION; FEMALE; IMMUNE RESPONSE; IMMUNIZATION; IN VITRO STUDY; MORPHOLOGY; MOUSE; MULTIPLE SCLEROSIS; NONHUMAN; OVERALL SURVIVAL; PARTICLE SIZE; PRIORITY JOURNAL; SOLVENT EFFECT; SUPPRESSOR CELL; T LYMPHOCYTE ACTIVATION; TOXICITY TESTING;

ANAPHYLAXIS; ANIMALS; BODY WEIGHT; CHEMISTRY, PHARMACEUTICAL; DELAYED-ACTION PREPARATIONS; DRUG CARRIERS; ENCEPHALOMYELITIS, AUTOIMMUNE, EXPERIMENTAL; FEMALE; IMMUNOLOGIC FACTORS; INJECTIONS, INTRAVENOUS; INJECTIONS, SUBCUTANEOUS; LACTIC ACID; MICE; MYELIN PROTEOLIPID PROTEIN; PARTICLE SIZE; PEPTIDE FRAGMENTS; POLYGLYCOLIC ACID; SOLUBILITY; SURFACE PROPERTIES; TIME FACTORS;

EID: 72149128473     PISSN: 01683659     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.jconrel.2009.09.002     Document Type: Article

References (40)

1. Goldsby R.A., Kindt T.J., Osborne B.A., and Kuby J. Immunology (2003), W.H. Freeman and Company, New York
2. Dunehoo A.L., Anderson M., Majumdar S., Kobayashi N., Berkland C., and Siahaan T.J. Cell adhesion molecules for targeted drug delivery. J. Pharm. Sci. 95 (2006) 1856-1872
3. Seminario M.-C., and Bunnell S.C. Signal initiation in T-cell receptor microclusters. Immunol. Rev. 221 (2008) 90-106
4. Kobayashi N., Kobayashi H., Gu L., Malefyt T., and Siahaan T.J. Antigen-specific suppression of experimental autoimmune encephalomyelitis by a novel bifunctional peptide inhibitor. J. Pharmacol. Exp. Ther. 322 (2007) 879-886
5. Kobayashi N., Kiptoo P., Kobayashi H., Ridwan R., Brocke S., and Siahaan T.J. Prophylactic and therapeutic suppression of experimental autoimmune encephalomyelitis by a novel bifunctional peptide inhibitor. Clin. Immunol. 129 (2008) 69-79
6. Murray J.S., Oney S., Page J.E., Kratochvil-Stava A., Hu Y., Makagiansar I.T., Brown J.C., Kobayshi N., and Siahaan T.J. Suppression of type 1 diabetes in NOD mice by bifunctional peptide inhibitor: modulation of the immunological synapse formation. Chem. Biol. Drug Des. 70 (2007) 227-236
7. Lofthouse S. Immunological aspects of controlled antigen delivery. Adv. Drug Del. Rev. 54 (2002) 863-870
8. Matzelle M.A., and Babensee J.E. Humoral immune responses to model antigen co-delivered with biomaterials used in tissue engineering. Biomaterials 25 (2004) 295-304
9. Bennewitz N.L., and Babensee J.E. The effect of the physical form of poly(lactic-co-glycolic acid) carriers on the humoral immune response to co-delivered antigen. Biomaterials 26 (2005) 2991-2999
10. Yoshida M., and Babensee J.E. Poly(lactic-co-glycolic acid) enhances maturation of human monocyte-derived dendritic cells. J. Biomed. Mater. Res. A 71 (2004) 45-54
11. de Lalla F., Rinaldi E., Santoro D., and Pravettoni G. Immune response to hepatitis B vaccine given at different injection sites and by different routes: a controlled randomized study. Eur. J. Epidemiol. 4 (1988) 256-258
12. Schellekens H. Factors influencing the immunogenicity of therapeutic proteins. Nephrol. Dial. Transplant. 20 (2005) vi3-vi9
13. Crommelin D.J.A., Sindelar R.D., and Meibohm B. Pharmaceutical Biotechnology: Fundamentals and Applications. 3 rd edition (2007), Informa Health Care, New York
14. Little S.R., Lynn D.M., Ge Q., Anderson D.G., Puram S.V., Chen J., Eisen H.N., and Langer R. Poly-beta amino ester-containing microparticles enhance the activity of nonviral genetic vaccines. Proc. Natl. Acad. Sci. U. S. A. 101 (2004) 9534-9539
15. Jiang W., Gupta R.K., Deshpande M.C., and Schwendeman S.P. Biodegradable poly(lactic-co-glycolic acid) microparticles for injectable delivery of vaccine antigens. Adv. Drug Deliv. Rev. 57 (2005) 391-410
16. Combadiere B., and Mahe B. Particle-based vaccines for transcutaneous immunization. Comp. Immunol. Microbiol. Infect. Dis. 31 (2008) 293-315
17. Kim H., and Burgess D.J. Effect of drug stability on the analysis of release data from controlled release microspheres. J. Microencapsul. 19 (2002) 631-640
18. Collins T.J. ImageJ for microscopy. BioTechniques 43 (2007) 25-30
19. Hofstetter H.H., Shive C.L., and Forsthuber T.G. Pertussis toxin modulates the immune response to neuroantigens injected in incomplete Freund's adjuvant: induction of Th1 cells and experimental autoimmune encephalomyelitis in the presence of high frequencies of Th2 cells. J. Immunol. 169 (2002) 117-125
20. ICH-Working-Group, Impurities: Guideline for Residual Solvents Q3C(R3), July 1997, p. 20.
21. Zolnik B.S., and Burgess D.J. Evaluation of in vivo-in vitro release of dexamethasone from PLGA microspheres. J. Control. Release 127 (2008) 127-145
22. Faisant N., Siepmann J., and Benoit J.P. PLGA-based microparticles: elucidation of mechanisms and a new, simple mathematical model quantifying drug release. Eur. J. Pharm. Sci. 15 (2002) 355-366
23. Woo B.H., Kostanski J.W., Gebrekidan S., Dani B.A., Thanoo B.C., and DeLuca P.P. Preparation, characterization and in vivo evaluation of 120-day poly(d, l-lactide) leuprolide microspheres. J. Control. Release 75 (2001) 307-315
24. Moioli E.K., Hong L., Guardado J., Clark P.A., and Mao J.J. Sustained release of TGF-beta3 from PLGA microspheres and its effect on early osteogenic differentiation of human mesenchymal stem cells. Tissue Eng. 12 (2006) 537-546
25. Goodin D.S., Cohen B.A., O'Connor P., Kappos L., and Stevens J.C. Assessment: the use of natalizumab (Tysabri) for the treatment of multiple sclerosis (an evidence-based review). Neurology 71 (2008) 766-773
26. Hoag H. Tysabri's troubles return. Nat. Biotechnol. 26 (2008) 1061
27. Aharoni R., Teitelbaum D., Leitner O., Meshorer A., Sela M., and Arnon R. Specific Th2 cells accumulate in the central nervous system of mice protected against experimental autoimmune encephalomyelitis by copolymer 1. Proc. Natl Acad. Sci. U. S. A. 97 (2000) 11472-11477
28. Blanchette F., and Neuhaus O. Glatiramer acetate: evidence for a dual mechanism of action. J. Neurol. 255 (2008) 26-36
29. Langer-Gould A., and Steinman L. Progressive multifocal leukoencephalopathy and multiple sclerosis: lessons from natalizumab. Curr. Neurol. Neurosci. Rep. 6 (2006) 253-258
30. Langer-Gould A., and Steinman L. What went wrong in the natalizumab trials?. Lancet 367 (2006) 708-710
31. Wang C., Gold B.G., Kaler L.J., Yu X., Afentoulis M.E., Burrows G.G., Vandenbark A.A., Bourdette D.N., and Offner H. Antigen-specific therapy promotes repair of myelin and axonal damage in established EAE. J. Neurochem. 98 (2006) 1817-1827
32. Luca M.E., Kel J.M., van Rijs W., Drijfhout J., Koning F., and Nagelkerken L. Mannosylated PLP(139-151) induces peptide-specific tolerance to experimental autoimmune encephalomyelitis. J. Neuroimmunol. 160 (2005) 178-187
33. Falk K., Rotzschke O., Santambrogio L., Dorf M.E., Brosnan C., and Strominger J.L. Induction and suppression of an autoimmune disease by oligomerized T cell epitopes: enhanced in vivo potency of encephalitogenic peptides. J. Exp. Med. 191 (2000) 717-730
34. Waeckerle-Men Y., von Allmen E.U., Gander B., Scandella E., Schlosser E., Schmidtke G., Merkle H.P., and Groettrup M. Encapsulation of proteins and peptides into biodegradable poly(d, l-lactide-co-glycolide) microspheres prolongs and enhances antigen presentation by human dendritic cells. Vaccine 24 (2006) 1847-1857
35. Jhunjhunwala S., Raimondi G., Thomson A.W., and Little S.R. Delivery of rapamicin to dendritic cells using degradable microparticles. J. Control. Release 133 (2009) 191-197
36. Luzardo-Alvarez A., Blarer N., Peter K., Romero J.F., Reymond C., Corradin G., and Gander B. Biodegradable microspheres alone do not stimulate murine macrophages in vitro, but prolong antigen presentation by macrophages in vitro and stimulate a solid immune response in mice. J. Control. Release 109 (2005) 62-76
37. Kennedy M., Torrance D., Picha K., and Mohler K. Analysis of cytokine mRNA expression in the central nervous system of mice with experimental autoimmune encephalomyelitis reveals that IL-10 mRNA expression correlates with recovery. J. Immunol. 149 (1992) 2496-2505
38. Lock C., Hermans G., Pedotti R., Brendolan A., Schadt E., Garren H., Langer-Gould A., Strober S., Cannella B., Allard J., Klonowski P., Austin A., Lad N., Kaminski N., Galli S.J., Oksenberg J.R., Raine C.S., Heller R., and Steinman L. Gene-microarray analysis of multiple sclerosis lesions yields new targets validated in autoimmune encephalomyelitis. Nat. Med. 8 (2002) 500-508
39. Hedegaard C.J., Krakauer M., Bendtzen K., Lund H., Sellebjerg F., and Nielsen C.H. T helper cell type 1 (Th1), Th2 and Th17 responses to myelin basic protein and disease activity in multiple sclerosis. Immunology 125 (2008) 161-169
40. Gold R., and Luehder F. Interleukin-17-extended features of a key player in multiple sclerosis. Am. J. Pathol. 172 (2008) 8-10